Relationship of p53 Overexpression on Cancers and Recognition by Anti-p53 T Cell Receptor-Transduced T Cells

Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1201, USA.
Human gene therapy (Impact Factor: 3.76). 11/2008; 19(11):1219-32. DOI: 10.1089/hgt.2008.083
Source: PubMed


Tumor suppressor p53 is reported to be an attractive immunotherapy target because it is mutated in approximately half of human cancers, resulting in inactivation and often an accumulation of the protein in the tumor cells. Only low amounts of protein are detectable in normal tissues. The differential display of antigen in normal versus tumor tissues has been reported to create an opportunity to target p53 by immunotherapy. We sought to determine the relationship between p53 expression and its recognition by cognate T cells in human tumors including common epithelial malignancies. Inasmuch as nonsense or missense p53 mutations may disrupt processing and presentation, we studied tumors with either identified wild-type or mutated p53, based on our gene-sequencing studies or published data. T cells transduced with a high-affinity, p53(264-272)-reactive T cell receptor (TCR) derived from HLA-A2.1 transgenic mice recognized a wide panel of human tumor lines. There was no significant correlation between p53 expression in tumors and recognition by the anti-p53 TCR-transduced T cells. This conclusion was based on the study of 48 cell lines and is in contrast to several prior studies that used only a limited number of selected cell lines. A panel of normal cells was evaluated for recognition, and some of these populations were capable of stimulating anti-p53 T cells, albeit at low levels. These studies raise doubts concerning the suitability of targeting p53 in the immunotherapy of cancer patients.

Download full-text


Available from: Azam V Nahvi, Jul 02, 2014
24 Reads
  • Source
    • "Wild-type p53 is a ubiquitously-expressed protein but the wild-type p53 protein expression in normal tissue is hardly detectable due to rapid degradation by a proteasome-dependent pathway, which eventually causes antigen presentation on HLA class I molecules [50], [51]. The specificity of CD8+ T cells to p53-accumulating tumors was recently investigated, leading to the observation that CD8+ T cells transduced with high affinity p53-specific T cell receptor gene could recognize not only p53-accumulating tumors but also tumors expressing wild-type p53, irrespective of the expression level of p53 protein, and normal cells such as peripheral blood stem cells and dendritic cells [52]. Because antigen presentation by professional APCs like DCs in non-inflammatory condition is known to induce tolerance, a constitutive presentation of wild-type p53 by DCs could be considered to induce tolerance of high-avidity p53-specific CD8+ T cells [53]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Analyses of NY-ESO-1-specific spontaneous immune responses in cancer patients revealed that antibody and both CD4(+) and CD8(+) T cell responses were induced together in cancer patients. To explore whether such integrated immune responses are also spontaneously induced for other tumor antigens, we have evaluated antibody and T cell responses against self/tumor antigen p53 in ovarian cancer patients and healthy individuals. We found that 21% (64/298) of ovarian cancer patients but no healthy donors showed specific IgG responses against wild-type p53 protein. While none of 12 patients with high titer p53 antibody showed spontaneous p53-specific CD8(+) T cell responses following a single in vitro sensitization, significant p53-specific IFN-γ producing CD4(+) T cells were detected in 6 patients. Surprisingly, similar levels of p53-specific CD4(+) T cells but not CD8(+) T cells were also detected in 5/10 seronegative cancer patients and 9/12 healthy donors. Importantly, p53-specific CD4(+) T cells in healthy donors originated from a CD45RA(-) antigen-experienced T cell population and recognized naturally processed wild-type p53 protein. These results raise the possibility that p53-specific CD4(+) T cells reflect abnormalities in p53 occurring in normal individuals and that they may play a role in processes of immunosurveillance or immunoregulation of p53-related neoplastic events.
    PLoS ONE 08/2011; 6(8):e23651. DOI:10.1371/journal.pone.0023651 · 3.23 Impact Factor
  • Source
    • "Some of the approaches that may increase the expression and function of the transgene are being studied, including the use of different vectors, the introduction of powerful promoters specific to T cells, and the employment of higher-affinity TCRs. Latest clinical trials are testing new TCRs that recognize a broad array of cancer antigens such as p53, gp100, carcinoembryonic antigen and the NY-ESO-1 antigen of the cancer testis [57–59], which may enable targeting of other cancer types in addition to melanoma. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Adoptive Cell Transfer (ACT) of Tumor-Infiltrating Lymphocytes (TIL) in combination with lymphodepletion has proven to be an effective treatment for metastatic melanoma patients, with an objective response rate in 50%-70% of the patients. It is based on the ex vivo expansion and activation of tumor-specific T lymphocytes extracted from the tumor and their administration back to the patient. Various TIL-ACT trials, which differ in their TIL generation procedures and patient preconditioning, have been reported. In the latest clinical studies, genetically engineered peripheral T cells were utilized instead of TIL. Further improvement of adoptive T cell transfer depends on new investigations which seek higher TIL quality, increased durable response rates, and aim to treat more patients. Simplifying this therapy may encourage cancer centers worldwide to adopt this promising technology. This paper focuses on the latest progress regarding adoptive T cell transfer, comparing the currently available protocols and discussing their advantages, disadvantages, and implication in the future.
    Clinical and Developmental Immunology 12/2010; 2010(1740-2522):260267. DOI:10.1155/2010/260267 · 2.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The genetic introduction of T cell receptor genes into T cells has been developed over the past decade as a strategy to induce defined antigen-specific T cell immunity. With the potential value of TCR gene therapy well-established in murine models and the feasibility of infusion of TCR-modified autologous T cells shown in a first phase I trial, the next key step will be to transform TCR gene transfer from an experimental technique into a robust clinical strategy. In this review, we discuss the different properties of the TCR transgene and transgene cassette that can strongly affect both the efficacy and the safety of TCR gene transfer.
    Cancer Immunology and Immunotherapy 03/2009; 58(5):809-22. DOI:10.1007/s00262-008-0649-4 · 3.94 Impact Factor
Show more